Amylyx Pharmaceuticals 配当と自社株買い

配当金基準チェック /06

Amylyx Pharmaceuticals配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.3%

バイバック利回り

総株主利回り	-0.3%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

新しいナラティブ • Apr 02

Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential

Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?

新しいナラティブ • Mar 19

Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges

Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?

新しいナラティブ • Mar 05

PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model

Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • Jan 27

Amylyx Pharmaceuticals: Back From The Dead

Summary Amylyx Pharmaceuticals has rebounded sharply since its nadir in 2024, driven by the acquisition of avexitide and renewed pipeline optimism. Avexitide targets post-bariatric hypoglycemia, an underserved market with no approved therapies and significant unmet need. Street sentiment is bullish on AMLX, but current valuation appears fair given projected sales and patient penetration. An analysis around Amylyx Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha

分析記事 • Sep 01

Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...

分析記事 • May 10

Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Apr 03

Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking

Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...

新しいナラティブ • Apr 01

Avexitide Launch In 2027 Will Strengthen Our Pipeline

Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.

Seeking Alpha • Feb 24

Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery

Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking Alpha

分析記事 • Dec 19

Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding

The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...

分析記事 • Dec 10

Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Nov 25

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking Alpha

分析記事 • Nov 04

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...

分析記事 • Sep 18

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...

Seeking Alpha • Jun 25

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking Alpha

分析記事 • Apr 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Unfortunately for some shareholders, the Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has dived 31% in the...

分析記事 • Mar 12

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Today is shaping up negative for Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders, with the analysts...

Seeking Alpha • Mar 09

An ALS Drug Fails Again

Summary The ALS drug (Relyvrio) had been put through a Phase II trial by its developer, Amylyx. Amylyx was already working on a Phase III trial, and they committed to withdrawing the drug if this trial showed no efficacy. Just like with the recent approvals in Alzheimer's, the patient advocacy groups took victory laps after Relyvrio was approved, and they were a big part of the pressure that made the FDA reverse its initial correct decision. Read the full article on Seeking Alpha

Seeking Alpha • Feb 23

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Summary Amylyx Pharmaceuticals' stock has rebounded by 50% since a rating downgrade in November, reflecting investor relief after Q4 earnings were in line with expectations. The company provided an earlier timeline for Phase 3 PHOENIX trial data, which will impact the market prospects of its ALS drug, Relyvrio. Positive PHOENIX trial data could boost Amylyx's stock by 200%, while negative data could send it down by at least 50%. Read the full article on Seeking Alpha

分析記事 • Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have been powering on, with a gain...

決済の安定と成長

配当データの取得

安定した配当: AMLXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: AMLXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Amylyx Pharmaceuticals 配当利回り対市場

AMLX 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (AMLX)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Pharmaceuticals)	2.1%
アナリスト予想 (AMLX) (最長3年)	0%

注目すべき配当: AMLXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: AMLXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: AMLXの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: AMLXが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/21 06:56
終値	2026/05/21 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Amylyx Pharmaceuticals, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。13

アナリスト	機関
Christopher Chen	Baird
null null	Baird
Joel Beatty	Baird

Amylyx Pharmaceuticals 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Expands Access to Avexitide and Advances Rare Disease Pipeline Toward 2027 Launch

Amylyx Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2026

Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Lucidity Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges

PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model

Co-Founder notifies of intention to sell stock

Amylyx Pharmaceuticals, Inc. to Report Q4, 2025 Results on Mar 03, 2026

Co-Founder recently sold US$228k worth of stock

Co-Founder notifies of intention to sell stock

Amylyx Pharmaceuticals: Back From The Dead

Co-Founder notifies of intention to sell stock

Amylyx Pharmaceuticals, Inc. Announces Nomination of Amx0318 as A Novel, Long-Acting Glp-1 Receptor Antagonist

Amylyx Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Price target increased by 13% to US$18.50

Price target increased by 10% to US$16.38

Co-Founder recently sold US$431k worth of stock

Amylyx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation

Price target increased by 8.6% to US$12.63

Amylyx Pharmaceuticals, Inc. to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Chief Legal Officer & General Counsel notifies of intention to sell stock

Amylyx Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Amylyx Pharmaceuticals, Inc. Presents New Exploratory Analyses from Phase 2 and Phase 2B Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia At Endocrine Society

New major risk - Revenue and earnings growth

Amylyx Pharmaceuticals, Inc. Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. Announces Positive Long-Term Results from Phase 2 Helios Clinical Trial of AMX0035 in People with Wolfram Syndrome

Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?

Amylyx Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 08, 2025

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2025

Amylyx Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Co-Founder recently sold US$74k worth of stock

Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking

Avexitide Launch In 2027 Will Strengthen Our Pipeline

New major risk - Shareholder dilution

Full year 2024 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery

Amylyx Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 04, 2025

Co-Founder exercised options to buy US$138k worth of stock.

Amylyx Pharmaceuticals Announces FDA Lifts the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding

Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?

New minor risk - Insider selling

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Consensus EPS estimates fall by 22%

Co-Founder exercised options to buy US$427k worth of stock.

Third quarter 2024 earnings released: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 25% to US$5.33

Amylyx Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2 Helios Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals, Inc. to Host Virtual Webcast to Discuss Topline Results from Phase 2 Helios Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Co-Founder recently sold US$59k worth of stock

Co-Founder exercised options to buy US$99k worth of stock.

Chief Financial Officer recently bought US$101k worth of stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Independent Chairman of the Board recently bought US$220k worth of stock

Consensus EPS estimates fall by 30%

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of Amx0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’S Disease Pathology and Neurodegeneration

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Amylyx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Index

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

New minor risk - Profitability

Investor sentiment improves as stock rises 15%

Amylyx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Investor sentiment deteriorates as stock falls 20%

Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

配当金基準チェック /06